Biotech Values

[Biowatch]

ALNY & BIIB colloborate on anti-PML RNAi therapeutic

[I missed this earlier. Clearly BIIB looking for a work around for PML. If they find something that works very well, Tysabri might even be used in Crohn's disease.]

"In September 2006, Alnylam and Biogen Idec announced a collaboration to develop RNAi therapeutics for the potential treatment of progressive multifocal leukoencephalopathy (PML). PML is caused by infection of the central nervous system with a virus called "JC virus" and can occur in certain immune-suppressed patients, including those receiving immunomodulatory therapies. Alnylam and Biogen Idec will initially conduct investigative research into the potential of using RNAi technology to develop therapeutics to treat PML. Under terms of the collaboration, Biogen Idec will fund all research and development activities."

http://www.alnylam.com/collaborations/index.asp